Printed from Voxsanity (voxsanity.com.au) — NCT07328854 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Head And Neck Cancer
Phase 3 Head and Neck Cancer Trial, Recruiting
NCT07328854
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been fully informed about the study and have signed a consent form agreeing to take part
- People aged between 18 and 75 years
- People who have been confirmed by tissue testing to have a specific type of nasopharyngeal cancer (a cancer at the back of the nose/throat) classified as non-keratinising, either differentiated or undifferentiated (also called WHO type II or III)
- People whose cancer has been staged as Stage II according to a specific international staging system (the 9th edition AJCC/UICC classification), covering certain combinations of tumour and lymph node involvement with no spread to distant parts of the body
- People with a performance status score of 70 or above on the KPS scale, meaning they are able to carry out normal activity with some effort (confirm with trial site)
- People with blood test results showing the bone marrow is working well enough — including white blood cell count, platelet count, and haemoglobin levels within required ranges (confirm with trial site for exact values)
- People whose cancer scans after three cycles of a specific combination of chemotherapy and immunotherapy show either a complete response (cancer not visible) or a partial response (cancer has shrunk)
- People whose blood test for a virus marker called EBV DNA has dropped to an undetectable level after the initial chemotherapy treatment
- People with liver and kidney function test results within acceptable ranges, as measured by specific blood tests (confirm with trial site for exact values)
Who may not be able to join:
- People whose nasopharyngeal cancer has come back after previous treatment or has spread to other parts of the body
- People who are pregnant or breastfeeding
- People who have had another type of cancer in the past, unless it was successfully treated and falls into specific categories such as certain skin cancers, early-stage cervical cancer, localised prostate cancer, or a non-invasive breast condition (confirm with trial site)
- People whose cancer in the head and neck area has already been treated with radiation therapy or surgery (other than a biopsy for diagnosis), or where the tumour has significant tissue breakdown that could make radiation therapy unsuitable
- People with other serious health conditions that could make participation risky or difficult, such as unstable heart disease, serious kidney or liver disease, poorly controlled diabetes, severe mental health conditions, or another active cancer
- People who have had a serious allergic reaction to any PD-1 immunotherapy drug (a type of cancer immune treatment) in the past
- People who have had a serious allergic reaction to any of the chemotherapy drugs used in this trial, including gemcitabine, docetaxel, albumin-bound paclitaxel, paclitaxel, or cisplatin
- People who need to take immune-suppressing medications long-term, including certain steroid medicines
- People with active tuberculosis, or who are currently being treated for tuberculosis, or who received tuberculosis treatment within the past year
- People whom the treating doctor considers unsuitable for the trial for other medical reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Ming-Yuan Chen, MD,PhD, Sun Yat-sen University
Phone: +86-20-87343361
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Ming-Yuan Chen
Registry
ClinicalTrials.gov
Start date
20 November 2025
Est. completion
30 June 2030
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Progress-Free Survival (PFS); Incidence of ≥3 grade adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.